Abstract 625P
Background
Tumor markers have been used for cancer screening and monitoring, yet their potential connection with air pollution remains largely unexplored. We aimed to examine the potential association between various air pollutants – including carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), PM2.5, and PM10 – and the levels of tumor markers (AFP, CEA, CA19-9, CA125, and PSA) within the general population.
Methods
Our study included 10,067 men and 9,598 women in its final analysis. We assessed each individual's annual average exposure to five distinct air pollutants: PM2.5, PM10, NO2, SO2, and CO. Additionally, we measured serum concentrations of AFP, CEA, CA19-9, CA125, and PSA.
Results
After adjusting for potential confounding factors, we discovered noteworthy associations. Both men and women demonstrated a negative correlation between annual average exposure to SO2 and PM10 and AFP concentration (all P < 0.05). In men, after multivariate adjustment, exposure to CO, NO2, SO2, and PM10 showed negative correlations with CEA concentration (all P < 0.05). Furthermore, in men, exposure to CO, NO2, and PM10 exhibited positive associations with PSA concentration after multivariate adjustment (all P < 0.05). Among women, a similar multivariate analysis indicated that SO2 exposure was negatively correlated with CEA concentration (all P < 0.05).
Conclusions
Our study presents the first evidence of a potential link between air pollution exposure and tumor markers within the general population. To establish the validity of these associations, further investigations employing prospective analyses are warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
392TiP - A prospective phase II study of individualized adjuvant therapy in patients with locally advanced hypopharyngeal cancer after neoadjuvant therapy
Presenter: Juyi Wen
Session: Poster Display
Resources:
Abstract
397P - Comparison between Y-site co-infusion versus standard dexamethasone for preventing hypersensitivity reactions from oxaliplatin administration: A randomized controlled trial
Presenter: jarearnjit Phavirunsiri
Session: Poster Display
Resources:
Abstract
398P - Evaluation of the effectiveness of denosumab therapy giant cell tumor of the pelvis
Presenter: Abbos Nurjabov
Session: Poster Display
Resources:
Abstract
399P - Long-term outcomes of patients with gastric cancer who received the best supportive care without any anticancer treatment
Presenter: Yohei Arihara
Session: Poster Display
Resources:
Abstract
401TiP - Oral opioid vs intravenous patient-controlled analgesia (PCA) with hydromorphone bolus-only or continuous infusion to maintain analgesia for severe cancer pain: A randomized phase III trial
Presenter: Cheng Huang
Session: Poster Display
Resources:
Abstract
407P - K-TrackTM: A streamlined personalized assay to detect molecular residual disease in solid tumors
Presenter: Nam Vo
Session: Poster Display
Resources:
Abstract
408P - Increased EGFR and MET expression and corresponding tumor microenvironment (TME) change in hepatocellular carcinoma (HCC) tissues after sorafenib (Sora) treatment
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
410P - Systematic evaluation of cell-free DNA fragmentation patterns for cancer diagnosis and enhanced cancer detection through integration of multiple fragmentations
Presenter: Xiangy-Yu Meng
Session: Poster Display
Resources:
Abstract
412P - Multiplex digital spatial profiling (DSP) of protein reveals distinct immune and molecular phenotypes in hepatocellular carcinoma
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
413P - Clinical utility of advanced features provided by circulating tumor DNA-based comprehensive genomic profiling
Presenter: Young-gon Kim
Session: Poster Display
Resources:
Abstract